DOT1L and breast carcinoma: In another study, EPZ004777-mediated DOT1L inhibition was found to be effective in increasing E-cadherin levels in breast cancer cells by suppressing key transcription factors involved in the epithelial–mesenchymal transition (EMT) [25].